{"id":"spironolactone-or-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Hyponatremia"},{"rate":null,"effect":"Gynecomastia (spironolactone)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Spironolactone blocks aldosterone receptors in the collecting duct, reducing sodium reabsorption and potassium excretion, while hydrochlorothiazide inhibits the sodium-chloride cotransporter in the distal convoluted tubule to increase urinary sodium and water loss. Together, they provide complementary diuretic and antihypertensive effects with spironolactone offsetting the potassium-wasting effects of the thiazide.","oneSentence":"This is a combination of two diuretics: spironolactone (a potassium-sparing aldosterone antagonist) and hydrochlorothiazide (a thiazide diuretic that promotes sodium and water excretion).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:53.216Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Edema associated with liver cirrhosis or renal disease"}]},"trialDetails":[{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04465123","phase":"PHASE3","title":"Early Sequential Nephron Blockade in Acute Heart Failure Patients: A Randomised, Controlled Study","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2020-08-13","conditions":"Acute Heart Failure, Acute Kidney Injury","enrollment":100},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18063,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Aldactone","HCTZ","Thiazide"],"phase":"phase_3","status":"active","brandName":"Spironolactone or hydrochlorothiazide","genericName":"Spironolactone or hydrochlorothiazide","companyName":"Chiang Mai University","companyId":"chiang-mai-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of two diuretics: spironolactone (a potassium-sparing aldosterone antagonist) and hydrochlorothiazide (a thiazide diuretic that promotes sodium and water excretion). Used for Hypertension, Heart failure with reduced ejection fraction, Edema associated with liver cirrhosis or renal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}